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Tissue factor pathway inhibitor-2 is induced by
fluid shear stress in vascular smooth muscle cells
and affects cell proliferation and survival
Johan Ekstrand, MD,a Anton Razuvaev, MD, PhD,a Lasse Folkersen, MSc,b Joy Roy, MD, PhD,a and
Ulf Hedin, MD, PhD,a Stockholm, Sweden
Objective: Vascular smooth muscle cells (SMCs) are exposed to fluid shear stress (FSS) after interventional procedures
such as balloon-angioplasty. Whereas the effects of hemodynamic forces on endothelial cells are explored in detail, the
influence of FSS on smooth muscle cell function is poorly characterized. Here, we investigated the effect of FSS on SMC
gene expression and function.
Methods: Laminar FSS of arterial level (14 dynes/cm2) was applied to SMC cultures for 24 hours in a parallel-plate flow
chamber. The effect of FSS on gene expression was first screened with microarray technology, and results further verified
by real time polymerase chain reaction (RT-PCR) and immunoblotting. Tissue factor pathway inhibitor-2 (TFPI-2) and
caspase-3 protein expression was studied in the rat carotid artery after balloon-injury, and the effect of TFPI-2 on SMC
DNA synthesis and apoptosis was examined in vitro.
Results: Microarrays identified TFPI-2 as one of the most differentially expressed gene by FSS in cultured SMCs (P <
.001). Gene set enrichment analysis revealed significant regulation of genes linked to proliferation, apoptosis, and cell
cycle regulation. TFPI-2 induction was confirmed by RT-PCR and immunoblotting demonstrating a more than 400-fold
(P < .001) increase in TFPI-2 mRNA in SMCs exposed to FSS compared with static controls, and a consistent protein
upregulation. Functionally, SMC proliferation was decreased by FSS (P < .001), and recombinant TFPI-2 was found to
inhibit SMC proliferation (P< .001) and induce SMC apoptosis as indicated by activation of caspase-3 (P< .01). In vivo,
TFPI-2 expression was found to be upregulated 5, 10, and 20 hours (P < .01) after rat carotid balloon injury, and
immunohistochemistry demonstrated TFPI-2 protein in FSS-exposed luminal SMCs, co-localized with caspase-3 in the
rat carotid neointima.
Conclusion: FSS influenced gene expression associated with cell growth and apoptosis in cultured SMCs and strongly
induced expression of TFPI-2 mRNA and protein. TFPI-2 was expressed in luminal, FSS-exposed SMCs together with
caspase-3 in the rat carotid neointima after balloon injury. Functionally, TFPI-2 may play a role in vessel wall repair by
regulating SMC proliferation and survival. Further studies are needed to elucidate the mechanisms by which TFPI-2
controls SMC function. (J Vasc Surg 2010;52:167-75.)
Clinical Relevance: In the arterial wall, endothelial cells are exposed to fluid shear stress imposed by the flowing blood.
However, after vascular interventions, where the endothelial layer is denuded and in intimal hyperplasia that develops,
luminal smoothmuscle cells are exposed to shear stress.We show that TFPI-2 expression is strongly augmented in smooth
muscle cells exposed to shear stress and that TFPI-2 co-localizes with caspase-3 in vivo. In addition, TFPI-2 inhibits
smooth muscle cell proliferation and induces apoptosis in vitro. The adaption of smooth muscle cells to shear stress is of
interest in understanding the pathophysiology behind intimal hyperplasia and restenosis.Hemodynamic forces influence vascular cell function.
Fluid shear stress (FSS), the tangential force imposed by
blood flow on endothelial cells (ECs) in the intact vessel,
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doi:10.1016/j.jvs.2010.02.282has profound effects on the biology of these cells and
regulates a multitude of EC functions1,2 as recently sum-
marized in an excellent review article.3 Whereas laminar
FSS is atheroprotective, turbulent FSS has been shown to
promote atherogenesis.4 Although FSS mainly affects ECs,
three-dimensional simulations have shown that smooth
muscle cells (SMCs) immediately underlying the internal
elastic lamina (IEL) can be exposed to FSS through IEL
fenestrations,5 whereas SMCs further from the IEL are
exposed to very low FSS levels. Following iatrogenic endo-
thelial denudation6 and in the healing response to injury,
SMCs are exposed to FSS as theymigrate across the IEL in the
process of intimal hyperplasia (IH). IH and SMC prolifera-
tion7 are central features of restenosis.8 The introduction of
stents eluting anti-proliferative drugs (DES) reduced resteno-
sis rates after coronary interventions.9 However, DES may be
associated with a higher degree of late in-stent thrombosis,
possibly due to impaired endothelial regeneration.10 Delayed
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which SMCs are exposed to FSS.
Although FSS has previously been shown to inhibit
SMC proliferation11 and induce Akt-mediated apoptosis,12
SMCs have been assumed to respond mainly to stretch
forces, and detailed information on the effect of FSS on
SMC molecular processes is lacking.13
Here, we investigated the effect of FSS on SMC gene
expression and function. FSS mediated significant regula-
tion of gene sets related to cell growth and survival, and a
prominent TFPI-2 mRNA and protein induction. In vitro,
TFPI-2 influenced SMC proliferation and apoptosis, and,
in vivo, TFPI-2 was found to be expressed in adluminal
SMCs in rat carotid neointima together with caspase-3,
supporting a role for TFPI-2 in the regulation of SMC
survival in intimal repair.
Cell culture. Rat aortic SMCs of passage 3-5 were
expanded in F-12 HAM media (Invitrogen, Carlsbad,
Calif) with 10% fetal calf serum (FCS) with ascorbic acid
(AA) and penicillin-streptomycin (PEST). Human iliac ar-
tery SMCs were cultured in F-12 HAM/15% FCS with AA
and PEST. Prior to all experiments, cells were synchronized
for 24 hours in F-12 HAM/0.1% bovine serum albumin
(BSA) with AA and PEST.
In vitro shear stress exposure. Confluent rat SMC
monolayers were exposed to arterial levels of non-pulsatile
FSS (14 dynes/cm2)14 for 24 hours in a parallel-plate flow
chamber, previously described elsewhere.15 Flow over the
cell culture was created by a hydrostatic gradient achieved
by culture media reservoirs above and below the chamber
with the fluid level in the upper reservoir maintained by a
roller pump (323E/D, Watson-Marlow, Wilmington,
Mass). FSS was calculated from the chamber volume flow
using the formula (6Q )/(b h2), where Q  flow
(3 mL/s),   viscosity (0.01 dyne second/cm2), b 
flow channel width (4.4 cm), and h flow channel height
(0.054 cm). FSS was laminar with an approximate Reyn-
olds number of 7.28 for a FSS level of 14 dynes/cm2. Cells
were inspected by phase-contrast microscopy to ensure cell
viability and to exclude cellular detachment. Experiments
were carried out at 37°C with 100% humidity and 5% CO2.
DNA synthesis and flow cytometric DNA analy-
sis. DNA synthesis in rat and human SMCs was mea-
sured using a BrDU colorimetric assay (Roche Diagnos-
tics, Basel, Switzerland). Cells were kept in suspension
on 96-multiwell plates after 24-hour static incubation or
FSS exposure. For experiments with recombinant human
TFPI-2 (rhTFPI-2; R&D Systems, Minneapolis, Minn),
rSMCs were seeded on 96-multiwell plates and treated
with various concentrations of rhTFPI-2 (0, 10, 50, 100
ng/mL) in serum-containing media (10% for rSMC and
15% for hSMC) for 24 hours. Cells were labeled with BrdU
for the last 3 hours of incubation, fixed, stained with
anti-BrdU antibody, and substrate solution added. Plates
were read at 370 nm in a Spectramax 340 ELISA-reader
(PerkinElmer, Waltham, Mass). For flow cytometric analy-
sis (FACS), FSS-exposed SMCs and static control cells
were fixed in 70% ethanol, permeabilized, and stainedwith Triton X-100/propidium iodide, and flow cytom-
etry performed.
Rat carotid injury. Male 350-450 g Sprague-Dawley
rats were anesthetized with 2% isoflurane, and the left
carotid exposed through a midline neck incision. A 2F
Fogarty balloon embolectomy catheter was introduced
through the left external carotid artery and advanced to the
common carotid artery. The balloon was inflated with
saline, withdrawn three times with rotation, the catheter
removed, and flow restored. All animal experiments were
approved by the Local Ethics Committee. Left common
carotid arteries were harvested at 0, 5, 10, and 20 hours
(n  3 in each group) after injury for real time polymerase
chain reaction (RT-PCR) analysis and at 2, 5, and 10 days
(n  3 in each group) for immunohistochemistry.
Immunohistochemistry. Immunohistochemistry re-
agents were fromBiocareMedical (Concord, Calif). Rat com-
mon carotid arteries were perfusion-fixed with 4% formalin,
harvested, and placed in the same fixative. Samples were
embedded in paraffin and sectioned (5 m). For negative
control, unspecific rabbit and mouse IgG antibodies were
used. Sections on glass slides were placed in tissue-clear solu-
tion 2 10minutes and then in decreasing concentrations of
ethanol (99%, 95%, 70%). Sections were washed with distilled
water, and epitopes retrieved by high-pressure boiling in Diva
buffer for 20 minutes, washed with Tris-buffered saline
(TBS), and blocked with Background Sniper solution for 20
minutes. Slides were incubated with antibodies against
TFPI-2 (Santa Cruz Biotechnology, Santa Cruz, Calif;
1:200), caspase-3 (Cell SignalingTechnology,Danvers,Mass;
1:50), von Willebrand factor (DAKO, Glostrup, Denmark;
1:1000), and SM -actin (DAKO; 1:500), diluted inDaVinci
Green solution at room temperature for 1 hour and subse-
quently washed three times in TBS. A probe-polymer system
with alkaline phosphatase was applied, and detection was
carried out using Vulcan Fast Red. Hematoxylin was used for
background staining. For TFPI-2 and caspase-3 double stain-
ings, Vulcan Fast Red was used to detect TFPI-2 and Ferengi
Blue for caspase-3 without background staining. Samples
were then dehydrated in 95% ethanol for 2 minutes and 99%
ethanol for 5 minutes, xylene for 1 minute, and then
mounted.
RNA isolation. Cell cultures were scraped from culture
dishes and suspended in sterile phosphate-buffered saline
(PBS). Rat arteries were homogenized in Trizol using a
Fastprep homogenizer (Thermo Scientific, Waltham,
Mass). Cell suspensions were centrifuged for 5 minutes at
900 rpm, and the pellets resuspended in 1 mL of Trizol
(Qiagen, Hilden, Germany). RNA isolation proceeded
according to the RNeasy kit manufacturer (Qiagen)
protocol. RNA was eluted in 50 l RNAse-free water.
RNA quality was determined using the Agilent Bioana-
lyzer 2100 (Agilent Technologies, Palo Alto, Calif).
RNA quantity was assessed using a Nanodrop 1000
spectrophotometer (Thermo Scientific).
cDNA synthesis and RT-PCR. One g of RNA was
suspended in RNAse-free water with 50 pmol/L random
hexamer primers (Amersham, Little Chalfont, England) at
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for 3 minutes. Eighteen l of mastermix consisting of 5X
reverse transcriptase-buffer, 0.1 M dithiothreitol, 25 mM
deoxyribonucleotide triphosphate, Superscript II Reverse
Transcriptase (Gibco, Billings, Mont), and RNase inhibi-
tors (Promega, Madison, Wisc) was added. Random hex-
amers were annealed to template RNA for 10 minutes at
25°C, and cDNA was synthesized for 50 minutes at 42°C.
The reaction was terminated at 94°C for 4 minutes. A
TFPI-2 Taqman assay was from Applied Biosystems (Carls-
bad, Calif; Assay ID: Rn00597628_m1). RT-PCR was
conducted with the ABI Prism 7900-HT sequence detec-
tor (Applied Biosystems). Samples were run in triplicate for
40 cycles, and threshold values normalized to the expres-
sion of -2-microglobulin, -glucoronidase, and glyceral-
dehyde 3-phosphate dehydrogenase. RQ Manager 1.2
Software (Applied Biosystems) was used for quantification
of gene expression using the comparative Ct/RQ method.
Microarray analysis. For microarray analysis, 5 g of
total RNA was used from each of three separate rSMC
cultures (FSS-exposed 24 hours, 14 dynes/cm2 [n  3],
and statically incubated [24 hours; n  3]) and from each
of the injured and noninjured one word rat carotid arteries.
Biotin-labelled cRNA was generated and hybridized to
Affymetrix Rat Expression 230 2.0microarrays, which were
stained, washed, and scanned according to manufacturer’s
protocol. All microarray analysis reagents and equipment
were from Affymetrix (Santa Clara, Calif). Significance of
change between static and shear conditions was calculated
using the pairwise comparison function of the MAS5.0
algorithm (Statistical Algorithms Description Document;
Affymetrix, 2002) for all three sample pairings. A large
number of probe sets had increase or decrease calls in all
three replicate experiments. In order to avoid multiple
testing problems, we focused on significantly regulated
probe sets with the highest signal-log ratio.
Immunoblotting. Immunoblotting was performed as
previously described for other antigens.16 To detect
TFPI-2 protein, we used a cell lysis buffer containing 50
mM Tris-HCl, pH 8.0; 150 mM NaCl; 0.2% SDS; 0.5%
sodium deoxycholate; 0.5% Triton X-100; 0.2 mM sodium
vanadate; 100 mM NaF; and 1 mM EDTA . A 4% to 20%
gradient gel (BioRad, Hercules, Calif) was used for electro-
phoresis. The primary TFPI-2 antibody was incubated
overnight with the nitrocellulose membrane and ECL
chemiluminescence was used for detection.
Apoptosis assay. SMCs were seeded onto 96-multiwell
plates and cultured in F-12 HAM in the presence of 0.2,
0.5 or 1.0 g/mL of rhTFPI-2 for 48 hours. Apoptosis
was determined using a luminometric assay for activated
caspase-3/7 (Caspase-Glo 3/7 Assay; Promega).
Statistical analysis. Statistical analysis was per-
formed using Statistica 6 software (StatSoft, Tulsa,
Okla). Graphs were created using the GraphPad Prizm 5
software (GraphPad Software, Inc, La Jolla, Calif). For
DNA synthesis and apoptosis experiments, Mann-Whit-
neyU test was used, and values.05 were considered to be
significant. Statistical significance for RT-PCR data wasassessed using a 99% confidence interval for the standard
error of the mean. Cell culture experiments were per-
formed in three to five independent experiments with at
least three replicates. Gene set enrichment analysis was
performed using the generally applicable gene set enrich-
ment method.17 We chose the analyzed sets as 2765
groups of genes defined in the biological process part of
the Gene Ontology,18 and computed the gene-set enrich-
ment analysis using a paired t-test between the static and
shear samples as a metric of change.
RESULTS
SMC proliferation and gene expression is regulated
by FSS. DNA synthesis in SMCs exposed to FSS (14
dynes/cm2) for 24 hours was decreased to 22.2% com-
pared with static controls (P  .001; Fig 1). FACS analysis
of cellular DNA content also showed decreased G1/
S-progression (Table I) and revealed a higher degree of
fragmented DNA in FSS-exposed cells compared with
static controls (24.24% vs 4.76%), indicating increased
apoptosis. Microarray analysis of RNA isolated from SMCs
Fig 1. DNA synthesis of SMCs under static conditions compared
with SMCs exposed to FSS (14 dynes/cm2) for 24 hours. DNA
synthesis asmeasured byBrdUuptakewas 22.2% to that of controls in
the FSS exposed cells.Data presented asmedian (vertical line) 10th
to 90th percentile (box). Min and max represented by whiskers and
outliers are denoted by dots. ***P .001.
Table I. Flow cytometric cell cycle analysis of statically
cultured rSMCs compared with FSS-exposed rSMCs
(14 dynes/cm2 for 24 hours)
Percentage of cells
Static Shear
Cell cycle phase 15 h 24 h 15 h 24 h
G0/G1 65.66 63.45 85.38 70.45
S 17.87 17.66 3.19 3.13
G2 12.03 14.27 6.67 2.18
Fragmented
DNA
4.44 4.76 4.62 24.24
G0, Gap 0; G1, gap 1; G2, gap 2; h, hours; S, synthesis.exposed to FSS and cells cultured under static baseline
GO:0006260 9.56E-07 152 DNA replication
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significantly increased and decreased calls (P  .05) in all
three replication experiments. Among the 50 most signifi-
cantly regulated gene sets, 32% (16/50) were involved in
cellular proliferation, apoptosis, and cell cycle regulation
according to Gene Ontology18 classification (Table II;
Supplementary Material 1 [online only]). Supplementary
Material 2 (online only) contains a full description of
regulation-direction, change magnitude, and significance
for all genes included in the Affymetrix Rat 230 2.0 mi-
croarrays. TFPI-2, urokinase plasminogen activator, and
granzyme B were the most upregulated individual genes,
whereas cadherin-11 and elastin were found to be down-
regulated (Table III). No significant changes were seen in
the expression of most EC marker genes, but some SMC
marker genes such as SM -actin and leiomodin were
decreased (Table IV).
Increased expression of TFPI-2 in SMCs exposed to
FSS. The increased TFPI-2 mRNA expression in microar-
ray analysis (114-fold, P .001; Table III) in FSS-exposed
SMCs was confirmed with RT-PCR on three independent
sample pairs, demonstrating an increased relative TFPI-2
mRNA quantity (437.8-fold, P .001; Fig 2A). Immuno-
blotting revealed a consistent increase in TFPI-2 protein
expression after 24 hours of FSS exposure compared with
static controls (Fig 2B).
TFPI-2 inhibits DNA synthesis and induces apo-
ptosis in SMCs. To determine if TFPI-2 was involved
in the antiproliferative effect of FSS, rat and human SMCs
were treated with rhTFPI-2, and DNA synthesis was ana-
lyzed. rhTFPI-2 inhibited serum-induced DNA synthesis in
rSMCs at concentrations of 0.05 and0.10g/mL (P .001)
comparedwith cells cultured in 15%FCS (Fig 3A). InhSMCs,
treatment with 0.10 g/mL inhibited DNA synthesis signif-
icantly (P  .001), whereas no significant differences were
seen at lower rhTFPI-2 concentrations (Fig 3B).
To study if TFPI-2 could affect SMC apoptosis, rSMCs
were treated with rhTFPI-2 at 0.2, 0.5, and 1.0 g/mL for
48 hours, and apoptosis was determined with an assay for
Table II. Continued
Ontology ID
P value
(BH method)
Ontology
set size Ontology name
GO:0045732 1.06E-06 25 Positive regulation of
protein catabolism
GO:0010033 1.12E-06 150 Response to organic
substance
GO:0006924 3.20E-06 23 Activated T-cell apoptosis
GO:0001501 3.20E-06 121 Skeletal development
GO:0006916 3.20E-06 196 Anti-apoptosis
GO:0043065 3.22E-06 225 Positive regulation of
apoptosis
GO:0007507 3.55E-06 299 Heart development
BH, Benjamini and Hochberg.
A complete description of regulated gene sets can be found in Supplemen-
tary Material 1 (online only).Table II. Gene ontology of 50 most significantly
regulated gene sets between static and FSS-exposed SMC
cultures, showing 32% (16/50) of gene sets related to
regulation of cellular proliferation, cell cycle regulation,
and apoptosis
Ontology ID
P value
(BH method)
Ontology
set size Ontology name
GO:0006414 1.85E-34 101 Translational elongation
GO:0006412 9.04E-31 209 Protein biosynthesis
GO:0007049 7.28E-27 247 Cell cycle
GO:0006979 1.68E-16 172 Response to oxidative
stress
GO:0007155 9.87E-16 367 Cell adhesion
GO:0008284 7.22E-15 414 Positive regulation of cell
proliferation
GO:0006457 2.12E-14 130 Protein folding
GO:0006096 1.36E-13 75 Glycolysis
GO:0001568 8.19E-13 104 Blood vessel development
GO:0051301 2.88E-12 127 Cell division
GO:0051726 7.88E-12 99 Regulation of cell cycle
GO:0030199 9.68E-12 57 Collagen fibril organization
GO:0001666 1.29E-11 323 Response to hypoxia
GO:0008285 4.74E-11 323 Negative regulation of cell
proliferation
GO:0006917 6.62E-11 232 Induction of apoptosis
GO:0016567 1.05E-10 85 Protein ubiquitination
GO:0030335 1.41E-10 114 Positive regulation of cell
migration
GO:0042060 1.72E-10 106 Wound healing
GO:0042493 2.04E-10 448 Response to drug
GO:0007568 4.95E-10 152 Aging
GO:0006413 7.03E-10 59 Translational initiation
GO:0007067 8.41E-10 89 Mitosis
GO:0042127 9.93E-10 186 Regulation of cell
proliferation
GO:0043066 1.10E-09 292 Negative regulation of
apoptosis
GO:0030968 3.53E-09 40 Unfolded protein response
GO:0006897 6.79E-09 118 Endocytosis
GO:0008283 9.64E-09 201 Cell proliferation
GO:0043627 1.17E-08 114 Response to estrogen
stimulus
GO:0001937 1.65E-08 30 Negative regulation of
endothelial cell
proliferation
GO:0009725 1.73E-08 104 Response to hormone
stimulus
GO:0006364 4.26E-08 54 rRNA processing
GO:0006915 4.56E-08 376 Apoptosis
GO:0001558 1.35E-07 60 Regulation of cell growth
GO:0001570 2.36E-07 87 Vasculogenesis
GO:0030198 2.47E-07 115 Extracellular matrix
organization and
biogenesis
GO:0015031 2.54E-07 351 Protein transport
GO:0045454 3.55E-07 59 Cell redox homeostasis
GO:0009612 4.53E-07 78 Response to mechanical
stimulus
GO:0042274 4.88E-07 10 Ribosomal small subunit
biogenesis
GO:0019941 8.12E-07 167 Modification-dependent
protein catabolism
GO:0045787 8.12E-07 30 Positive regulation of
progression through cell
cycle
GO:0019915 8.59E-07 30 Sequestering of lipidactivated caspase-3/7. An increase in caspase-3/7 activity
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TFPI-2 (P  .01; Fig 4).
TFPI-2 and caspase-3 colocalize in adluminal
SMCs in rat carotid neointima. Compared with baseline
conditions (0 hours), TFPI-2mRNA levels in balloon-injured
Table III. Ten most up- and down-regulated genes in
rSMCs exposed to FSS (14 dynes/cm2) for 24 hours
Gene name Fold change P value
Upregulated
Tissue factor pathway inhibitor 2 114.00 .001
Dual-specificity phosphatase 2 109.96 .001
Plasminogen activator, urokinase 92.60 .001
Matrix metallopeptidase 3 71.85 .001
Glutathione-S-transferase, alpha
type 2 58.36 .001
Chemokine (C-C motif) ligand 2 46.30 .001
Similar to potassium channel
tetramerisation domain-containing
protein 4 45.25 .001
Granzyme B 44.23 .001
Dual-specificity phosphatase 5 41.27 .001
Cystatin 10 (chondrocytes)
(predicted) 39.40 .001
Downregulated
Cadherin 11 68.60 .001
Aminoadipate-semialdehyde synthase 67.04 .001
Similar to A830059I20Rik protein 55.71 .001
Elastin 46.30 .001
Kinesin family member 2C 42.22 .001
Visinin-like 1 41.27 .001
Ankyrin repeat and SOCS box-
containing protein 12 38.50 .001
Shugoshin-like 2 (S. pombe) 38.51 .001
Visinin-like 1 36.76 .001
G protein-coupled receptor, family C,
group 5, member B 36.76 .001
P  .0025 for all changes.
A description of all individually regulated genes can be found in Supplemen-
tary Material 2 (online only).
Table IV. Expression of endothelial cell markers (A) and
smooth muscle cell markers (B) in rSMCs following
exposure to FSS (14 dynes/cm2) for 24 hours
Fold change P value
A. Endothelial cell markers
vWF No change —
PECAM No change —
Cadherin 5 No change —
Selectin, EC No change —
Endoglin No change —
CD248 antigen, endosialin No change —
B. Smooth muscle cell markers
-SMA 1.953 .001
Myosin, heavy polypeptide 11 No change —
Leiomodin 1 7.290 .001
Transgelin No change —
Myocardin No change —
-SMA, Smooth muscle -actin; EC, endothelial cell; PECAM, platelet
endothelial cell adhesion molecule; vWF, Von Willebrand Factor.rat carotid arteries were significantly (P  .01) increased53.19-, 76.18-, and 14.08-fold at 5, 10, and 20 hours after
injury, respectively (Fig 5), as shown by microarray analysis.
To investigate TFPI-2 protein expression in SMCs exposed to
FSS in vivo, immunohistochemistry was performed 2, 5, and
10 days after injury. As previously described in this model, a
neointima is formed in response to the balloon injury with
adluminal SMCs that are exposed to FSS instead of ECs. The
absence of ECs in the injured artery was demonstrated with
von Willebrand Factor staining (Fig 6A, B), and the presence
of SMCs in themedia and neointimawere confirmedwith SM
-actin staining (Fig 6C,D). TFPI-2 proteinwas not detected
in control arteries (Fig 7A), but weak TFPI-2 staining was
observed superficially in the media 2 days after injury, and a
progressive increase in stainingwas seen in adluminal SMCs in
the neointima 5 and 10 days after injury (Fig 7B-D). Apopto-
tic activity was determined by staining for caspase-3 10 days
after injury, which showed positive cells adluminally (Fig 7E)
and a colocalization with TFPI-2 expressing cells (Fig 7F).
DISCUSSION
SMCs are central cellular components in vessel wall
repair7 after iatrogenic vascular injury, when ECs are de-
nuded and SMCs become exposed to hemodynamic forces.
Whereas regulation of EC function by FSS has been char-
acterized in detail, information on the effects of FSS on
SMCs is scarce. Here, we demonstrated that FSS regulate
SMC gene expression associated with proliferation and
apoptosis and induce expression of TFPI-2. TFPI-2 was
found to decrease SMC proliferation and induce apoptosis
Fig 2. Real-time PCR (A) demonstrating a 437.8-fold increase in
TFPI-2 mRNA (mean with standard error of the mean), and (B)
Western blot demonstrating an upregulation of TFPI-2 protein (at
32 kDa) in cells exposed to FSS (14 dynes/cm2) for 24 hours
compared with static controls. ***P  .001.in vitro. After rat carotid balloon injury, TFPI-2 was ex-
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posed to shear forces. The ability of TFPI-2 to inhibit
proliferation of SMCs and to mediate SMC apoptosis sug-
gests a central role for FSS and TFPI-2 in the control of
SMC survival in intimal repair.
FSS regulates cellular function in the vessel wall and
may control several EC processes1-4 as well as SMC prolif-
eration.11 Here, we demonstrated that FSS has a striking
impact on the expression of genes involved in processes
Fig 3. (A) BrdU incorporation in rat SMCs following treatment
with rhTFPI-2. Treatment with rhTFPI-2 at 50 and 100 ng/mL in
10% fetal calf serum significantly inhibited SMC DNA synthesis.
(B) BrdU incorporation in human SMCs following treatment with
rhTFPI-2. Treatment with rhTFPI-2 at 100 ng/mL in 15% fetal
calf serum significantly inhibited SMC DNA synthesis. Data ex-
pressed as median (vertical line)  10th to 90th percentile (box)
withmin andmax represented by whiskers. Outliers are denoted by
dots. ns, not significant. ***P  .001.governing cellular growth and survival, when comparedwith static baseline conditions. Microarray analysis showed
a prominent upregulation of TFPI-2 and urokinase plas-
minogen activator, whereas cadherin 11 and elastin were
among the most downregulated genes. Few SMC differen-
tiation markers were affected by FSS, indicating that hemo-
dynamic conditions do not induce significant changes in
phenotype in subcultivated SMCs, at least not under 24-
hour FSS exposure. In addition, SMCs did not express
more EC markers after 24-hour FSS exposure, in contrast
to a previous report where FSS-exposed p53 null mouse
SMCs were shown to transdifferentiate to an EC-like phe-
notype.19 These contradicting results may be explained by
differences in the cell types used in the two studies.
TFPI-2 is a secreted 25-32 kDa Kunitz-type domain
serine protease inhibitor previously called placental protein
5 after the discovery of large amounts in human placenta,20
but subsequently named TFPI-221 due to structural simi-
Fig 4. Apoptosis as measured by caspase 3/7 activity. Treatment
with rhTFPI-2 significantly increased rSMC apoptosis at 0.5 and
1.0 ug/mL. Data expressed as mean  SEM. ns, not significant.
**P  .01.
Fig 5. TFPI-2mRNA signal as determined bymicroarray analysis
at 0 hours (n 3), 5 hours (n 3), 10 hours (n 3), and 20 hours
(n  3) after balloon injury to the rat carotid. Data expressed as
mean  SEM. **P  .01.larity with tissue factor pathway inhibitor 1 (TFPI-1).22
s: Int
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artery SMCs, whereas SMCs of atherosclerotic vessels showed
more TFPI-2 staining.23 In human serum, TFPI-2 is present
at 0.43 and 0.49 g/L for men and nonpregnant women,
respectively.24 Functionally, TFPI-2 has several vascular im-
plications; it has been shown to inhibit EC proliferation in-
duced by VEGF,25 which may be important for EC regener-
ation after vascular injury. It has been shown to inhibit MMP
2, 9, 13,26 and possibly MMP-1, but the results are conflict-
ing.27 In addition, TFPI-2 has anticoagulant properties, in-
hibiting factor XIa and the factor VIIa/tissue factor complex,
but also plasmin and kallikrein.28 In an early report, TFPI-2
was reported to inhibit thrombin,29 but later there has been
contradictory evidence.30
Increased SMC expression of TFPI-2 mRNA and pro-
tein in response to FSS in vitro was confirmed with RT-
PCR and immunoblotting. TFPI(-1) was previously re-
ported to be regulated by FSS in ECs,31,32 but no such
finding has been reported regarding TFPI-2. TFPI-2 pro-
tein was also detected in adluminal SMCs in the rat carotid
Fig 6. Immunohistochemistry of the rat carotid artery.
10 days after balloon injury (B, D), with visible neointi
Willebrand Factor (vWF) staining was seen (B) as compa
served as positive control for vWF. Medial and neointima
(C; control, D; 10 days after balloon injury). Arrowheadneointima 5 and 10 days after injury. The prominent aug-mentation of TFPI-2 mRNA and protein expression in
response to FSS in vitro and the positive TFPI-2 protein
staining in adluminal SMCs in the rat carotid neointima,
where these cells become exposed to hemodynamic forces,
support a critical role for FSS in the induction of TFPI-2 by
SMCs and the presence of TFPI-2 at high local concentra-
tions in the adluminal neointima.
In the rat carotid balloon injury model, the EC-
denuded luminal surface is coveredbyplatelets during the first
24 hours after injury. As SMCsmigrate across the IEL, SMCs
cover the luminal surface and become exposed to FSS. This is
followed by resolution of the luminal thrombosis and recon-
stitution of a nonthrombogenic surface by SMCs.33 Mecha-
nistically, this has been attributed to SMC surface heparan
sulfates and expression of iNOS.34 Given the anticoagulant
properties of TFPI-2, TFPI-2 expressed by adluminal SMCs
may contribute to the non-thrombogenic state of the neoin-
timal surface in the absence of ECs.
TFPI-2 mRNA was upregulated at 5 hours after bal-
loon injury to the rat carotid, and was further augmented at
l lumen at top of each picture. Uninjured (A, C) and at
rmation. In the injured artery, no positive luminal von
ith the uninjured control (A). Perivascular capillaries (*)
were identified as SMCs by positive SM -actin staining
ernal elastic lamina.Vesse
ma fo
red w
l cells10 hours after injury, with a decline after 20 hours. This is
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July 2010174 Ekstrand et almost likely related to the injury as such and not a direct
effect of SMC FSS exposure, since SMCs at these early time
points have not yet migrated across the IEL. In support of
this notion, a weak staining for TFPI-2 protein was also
observed in the media 2 days after injury. Together, these
findings imply that TFPI-2 induction may be both a direct
response to injury and, later, a response to FSS in adluminal
SMCs.
Although intimal repair after vascular injury is domi-
nated by the action of multiple mitogens and SMC prolif-
eration, numerous anti-proliferative mechanisms are also
engaged.7 In addition, apoptosis may regulate intimal
thickening and apoptosis of SMCs has previously been
detected in adluminal cells of IH after balloon injury.35
Here, we demonstrated that TFPI-2 reduced SMC prolif-
eration and induced apoptosis in vitro. We also found that
TFPI-2 was expressed in caspase-3 positive, adluminal
SMCs, in support of the notion that TFPI-2 is involved in
SMC survival. Since the focus of this study was to investi-
gate the influence of FSS on SMCs, and adluminal cells
become exposed to hemodynamic forces as EC regenera-
tion in the rat carotid injury model remains incomplete, this
model may adequately correlate to the in vitro conditions
tested. FSS-induced TFPI-2 expression in adluminal SMCs
may therefore play a critical role in intimal SMC turnover,
which may in part explain why high FSS has been shown to
inhibit or even induce regression36 of IH. In support of
these findings, TFPI-2 was previously suggested as a tumor
suppressor37 and to mediate apoptosis of human glioblas-
toma cells.38 In contrast, TFPI-2 has been described as a
mitogen for bovine aortic SMCs39 using TFPI-2 purified
Fig 7. Immunohistochemistry of the rat carotid artery
protein staining in the vessel wall. At 2 days after inju
adluminal SMCs. At days 5 (C) and 10 (D), increased T
These cells also expressed activated caspase-3 (E) at day
10 days after injury (F) showed colocalization (purple) of
Internal elastic lamina.from human umbilical vein ECs and recombinant TFPI-2produced in baby hamster kidney cells. This discrepancy
may be due to species and protein structure differences,
since the recombinant TFPI-2 used in our study ends at
amino acid residue 213 and does not contain the last 22
residues of the C-terminal region but with the three Kunitz
domains of the native protein intact. The full amino acid
sequence of TFPI-2 in the mentioned study was not dis-
closed.
In summary, we show that arterial levels of FSS influ-
ence SMC gene expression, inhibit SMC proliferation, and
induce apoptosis. TFPI-2 was found to be one of the most
differentially regulated genes by FSS in vitro, and TFPI-2
protein was expressed in luminal SMCs together with
caspase-3 after endothelial denudation in the rat carotid
artery. The observed ability of TFPI-2 to influence SMC
proliferation and apoptosis in vitro suggest that TFPI-2
expression by SMCs in response to FSS may play an impor-
tant role in the control of SMC turnover in the intima
during vascular repair.
Study limitations. The use of recombinant human
TFPI-2 to treat rat cells in this study may impose a limita-
tion. However, considerable species homology and se-
quence identity has been shown between rat, human,
mouse, and bovine TFPI-2.40
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